References

Pharmacology of antagonism of GPCR

10.1248/bpb.b22-00143 · 2022 · External reference

Inverse, protean, and ligand-selective agonism: matters of receptor conformation

10.1096/fj.00-0438rev · 2001 · External reference

Tactical approaches to interconverting GPCR agonists and antagonists

10.1021/acs.jmedchem.5b00982 · 2016 · External reference

Selective blockade of adrenoceptive beta receptors in the heart

10.1111/j.1476-5381.1968.tb00444.x · 1968 · External reference

Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives

10.1021/jm00163a036 · 1990 · External reference

Naloxone treatment of opiate dependence. A progress report

10.1001/jama.1971.03180260050019 · 1971 · External reference

The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists

10.1073/pnas.73.11.4215 · 1976 · External reference

The development of cimetidine: 1964–1976. A human story

10.1097/00004836-199410000-00017 · 1994 · External reference

Approaches for differentiation and interconverting GPCR agonists and antagonists

10.1007/978-1-4939-7465-8_12 · 2018 · External reference

Structure, function and drug discovery of GPCR signaling

10.1186/s43556-023-00156-w · 2023 · External reference

Ligand control of coregulator recruitment to nuclear receptors

10.1146/annurev.physiol.66.032802.154710 · 2005 · External reference

Mechanisms and physiological implications of cooperative gating of clustered ion channels

10.1152/physrev.00022.2021 · 2022 · External reference

The capsaicin receptor: a heat-activated ion channel in the pain pathway

10.1038/39807 · 1997 · External reference

Regulation of body temperature by the nervous system

10.1016/j.neuron.2018.02.022 · 2018 · External reference

Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis

10.1016/j.pharmthera.2020.107474 · 2020 · External reference

Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia

10.1523/jneurosci.5150-09.2010 · 2010 · External reference

Discovery of benzopyridone-based transient receptor potential vanilloid 1 agonists and antagonists and the structural elucidation of their activity shift

10.1021/acs.jmedchem.0c00982 · 2021 · External reference

Effect of capsaicin on thermoregulation: an update with new aspects

10.1080/23328940.2015.1048928 · 2015 · External reference

Dopamine D3 receptor, cognition and cognitive dysfunctions in neuropsychiatric disorders: from the bench to the bedside

10.1007/7854_2022_326 · 2023 · External reference

Neuronal dopamine D3 receptors: translational implications for preclinical research and CNS disorders

10.3390/biom11010104 · 2021 · External reference

2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design

10.1016/j.bmcl.2024.129654 · 2024 · External reference

Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents

10.1021/jm5019274 · 2015 · External reference

Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action

10.1021/jm801354e · 2009 · External reference

Design and synthesis of bitopic 2-phenylcyclopropylmethylamine (PCPMA) derivatives as selective dopamine D3 receptor ligands

10.1021/acs.jmedchem.9b01835 · 2020 · External reference

Aminergic GPCR-ligand interactions: a chemical and structural map of receptor mutation data

10.1021/acs.jmedchem.8b00836 · 2019 · External reference

2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts

10.1021/acs.jmedchem.9b01105 · 2020 · External reference

5-HT(2C) receptor structures reveal the structural basis of GPCR polypharmacology

10.1016/j.cell.2018.01.001 · 2018 · External reference

A novel “activation switch” motif common to all aminergic receptors

10.1021/acs.jcim.3c00732 · 2023 · External reference

Novel regulatory mechanisms for expression of drug metabolism-related factors

10.1248/yakushi.24-00141 · 2024 · External reference

The role of pregnane X receptor (PXR) in substance metabolism

10.3389/fendo.2022.959902 · 2022 · External reference

Advances in drug resistance of osteosarcoma caused by pregnane X receptor

10.1080/03602532.2024.2366948 · 2024 · External reference

Strategies for developing pregnane X receptor antagonists: implications from metabolism to cancer

10.1002/med.21648 · 2020 · External reference

SPA70 is a potent antagonist of human pregnane X receptor

10.1038/s41467-017-00780-5 · 2017 · External reference

Building a chemical toolbox for human pregnane X receptor research: discovery of agonists, inverse agonists, and antagonists among analogs based on the unique chemical scaffold of SPA70

10.1021/acs.jmedchem.0c02201 · 2021 · External reference

Designing out PXR activity on drug discovery projects: a review of structure-based methods, empirical and computational approaches

10.1021/acs.jmedchem.0c02245 · 2021 · External reference

Chemical manipulation of an activation/inhibition switch in the nuclear receptor PXR

10.1038/s41467-024-48472-1 · 2024 · External reference

The role of peroxisome proliferator-activated receptors (PPAR) in immune responses

10.1016/j.metabol.2020.154338 · 2021 · External reference

Transcriptional and epigenomic regulation of adipogenesis

10.1128/mcb.00601-18 · 2019 · External reference

PPAR control of metabolism and cardiovascular functions

10.1038/s41569-021-00569-6 · 2021 · External reference

Fat and beyond: the diverse biology of PPARγ

10.1146/annurev.biochem.77.061307.091829 · 2008 · External reference

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARγ) recruits PPARγ-coactivator-1α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro

10.1210/me.2005-0171 · 2006 · External reference

Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility

10.1016/j.bmc.2013.02.003 · 2013 · External reference

Structural biology inspired development of a series of human peroxisome proliferator-activated receptor gamma (PPARγ) ligands: from agonist to antagonist

10.3390/ijms24043940 · 2023 · External reference

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities

10.1124/mol.107.041202 · 2008 · External reference

Partial agonists activate PPARγ using a helix 12 independent mechanism

10.1016/j.str.2007.07.014 · 2007 · External reference

Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis

10.1016/j.bmc.2005.03.027 · 2005 · External reference

Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations

10.1016/j.bmcl.2015.05.025 · 2015 · External reference

Structural biology-based exploration of subtype-selective agonists for peroxisome proliferator-activated receptors

10.3390/ijms22179223 · 2021 · External reference

Molecular modeling of allosteric site of isoform-specific inhibition of the peroxisome proliferator-activated receptor PPARγ

10.3390/biom12111614 · 2022 · External reference

Arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists covalently bind to the PPARγ ligand binding domain with a unique binding mode

10.1016/j.bmcl.2022.128676 · 2022 · External reference

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)

10.1126/science.6189183 · 1983 · External reference

HIV/AIDS

10.1038/466s1a · 2010 · External reference

Molecular mechanism of HIV-1 entry

10.1016/j.tim.2019.06.002 · 2019 · External reference

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5

10.1038/384179a0 · 1996 · External reference

10.1186/2047-783x-16-1-1 · 2011 · Admitted local publication

Entry inhibitors in the treatment of HIV-1 infection

10.1016/j.antiviral.2009.07.022 · 2010 · External reference

HIV entry inhibitors

10.1016/s0140-6736(07)61052-6 · 2007 · External reference

The V2 domain of HIV gp120 mimics an interaction between CD4 and integrin ⍺4β7

10.1371/journal.ppat.1011860 · 2023 · External reference

Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions

10.1073/pnas.2634931100 · 2003 · External reference

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

10.1038/31405 · 1998 · External reference

Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist

10.1021/ar4002735 · 2014 · External reference

Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis

10.1111/cbdd.12075 · 2013 · External reference

Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4

10.1016/j.virol.2005.06.008 · 2005 · External reference

Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120

10.1016/j.str.2008.09.005 · 2008 · External reference

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state

10.1371/journal.ppat.1000360 · 2009 · External reference

Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study

10.1128/aac.03339-14 · 2014 · External reference

Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown

10.2174/092986710790980005 · 2010 · External reference

Molecular characterization of a peripheral receptor for cannabinoids

10.1038/365061a0 · 1993 · External reference

The central cannabinoid receptor type-2 (CB2) and chronic pain

10.1080/00207454.2016.1257992 · 2017 · External reference

Developing the cannabinoid receptor 2 (CB2) pharmacopoeia: past, present, and future

10.1016/j.tips.2022.06.010 · 2022 · External reference

Brain cannabinoid receptor 2: expression, function and modulation

10.1038/aps.2016.149 · 2017 · External reference

Crystal structure of the human cannabinoid receptor CB2

10.1016/j.cell.2018.12.011 · 2019 · External reference

Flipping the GPCR switch: structure-based development of selective cannabinoid receptor 2 inverse agonists

10.1021/acscentsci.3c01461 · 2024 · External reference

Structural basis of selective cannabinoid CB(2) receptor activation

10.1038/s41467-023-37112-9 · 2023 · External reference

Highly selective, amine-derived cannabinoid receptor 2 probes

10.1002/chem.201904584 · 2020 · External reference

Single-position ligand modifications tune CB(2)R activity by targeting the toggle switch

10.1039/d6sc00062b · 2026 · External reference

Vitamin D and health: perspectives from mice and man

10.1359/jbmr.080420 · 2008 · External reference

Biology and mechanisms of action of the vitamin D hormone

10.1016/j.ecl.2017.07.001 · 2017 · External reference

Vitamin D in central nervous system: implications for neurological disorders

10.3390/ijms25147809 · 2024 · External reference

Vitamin D and autoimmune diseases

10.1016/j.lfs.2019.116744 · 2019 · External reference

Impact of vitamin D and vitamin D receptor activator in diabetic nephropathy

2025 · External reference

Vitamin D, disease and therapeutic opportunities

10.1038/nrd3318 · 2010 · External reference

Identification of a highly potent vitamin D receptor antagonist: (25S)-26-adamantyl-25-hydroxy-2-methylene-22,23-didehydro-19,27-dinor-20-epi-vitamin D3 (ADMI3)

10.1016/j.abb.2006.11.026 · 2007 · External reference

Synthesis and structure-activity relationships of TEI-9647 derivatives as Vitamin D3 antagonists

10.1016/j.jsbmb.2004.03.046 · 2004 · External reference

Vitamin D and its synthetic analogs

10.1021/acs.jmedchem.9b00208 · 2019 · External reference

Structural analysis of VDR complex with ZK168281 antagonist

10.1021/acs.jmedchem.0c00656 · 2020 · External reference

Crystal structures of rat vitamin D receptor bound to adamantyl vitamin D analogs: structural basis for vitamin D receptor antagonism and partial agonism

10.1021/jm8004477 · 2008 · External reference

Ligand recognition by vitamin D receptor: Total alanine scanning mutational analysis of the residues lining the ligand binding pocket of vitamin D receptor

10.2174/156802606777864881 · 2006 · External reference

Targeting adenosine A2A receptors in Parkinson's disease

10.1016/j.tins.2006.09.004 · 2006 · External reference

Therapeutic potentials of A2B adenosine receptor ligands: current status and perspectives

10.2174/1381612825666190717105834 · 2019 · External reference

A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy

10.1016/j.csbj.2015.03.008 · 2015 · External reference

Inhibition of A(2A) adenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455

10.3389/fphar.2017.00888 · 2017 · External reference

Adenosine A2A receptor as a drug discovery target

10.1021/jm4011669 · 2014 · External reference

The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist

10.1016/s0022-3565(25)12287-8 · 1996 · External reference

The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist

10.1111/j.1476-5381.1995.tb15923.x · 1995 · External reference

8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists

10.1016/s0968-0896(98)00025-x · 1998 · External reference

The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist

10.1126/science.1164772 · 2008 · External reference

GPCR agonist-to-antagonist conversion: enabling the design of nucleoside functional switches for the A(2A) adenosine receptor

10.1021/acs.jmedchem.2c00462 · 2022 · External reference

Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands

10.1021/jm201229j · 2012 · External reference

Etiology of hormone receptor-defined breast cancer: a systematic review of the literature

10.1158/1055-9965.1558.13.10 · 2004 · External reference

Estrogen receptor alpha and ESR1 mutations in breast cancer

10.1007/978-3-031-11836-4_10 · 2022 · External reference

Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties

10.1021/jm970019l · 1997 · External reference

Steroidal affinity labels of the estrogen receptor alpha. 4. Electrophilic 11beta-aryl derivatives of estradiol

10.1021/jm990179s · 2000 · External reference

Identification of covalent attachment site of antiestrogenic estradiol 11 beta-derivatives on human estrogen receptor alpha ligand-binding domain

10.1016/j.jsbmb.2005.09.006 · 2006 · External reference

Synthesis and evaluation of 11β-(4-substituted phenyl) estradiol analogs: transition from estrogen receptor agonists to antagonists

10.1016/j.bmc.2012.04.041 · 2012 · External reference

New insights into GPCR coupling and dimerisation from cryo-EM structures

10.1016/j.sbi.2023.102574 · 2023 · External reference

AI-driven GPCR analysis, engineering, and targeting

10.1016/j.coph.2023.102427 · 2024 · External reference